Former Pfizer CEO, finance chief step back from Starboard’s activist campaign

Former Pfizer CEO, finance chief step back from Starboard’s activist campaign


Ian Read, chairman and chief executive officer of Pfizer, speaks as President Donald Trump, left, listens during an announcement on a new pharmaceutical glass packaging initiative in the Roosevelt Room of the White House in Washington, D.C., July 20, 2017. 

Andrew Harrer | Bloomberg | Getty Images

Former Pfizer CEO Ian Read and ex-CFO Frank D’Amelio said Wednesday evening that they would step away from Starboard Value’s campaign at the struggling pharmaceutical giant, just days after news of the activist’s stake broke.

Read and D’Amelio said they were “fully supportive” of Pfizer CEO Albert Bourla in a joint statement made via an investment bank and confirmed to be authentic. The duo had been in contact with a number of directors shortly before news of Starboard’s stake broke Sunday evening, according to people familiar with the matter.

“We are confident that over time they will deliver shareholder value,” the two former executives said of Pfizer’s current board and management. The company’s shares are essentially flat for the year and are off by roughly 50% from their 2021 highs.

The about face comes as Pfizer’s board grapples with the activist’s efforts, and just days before Starboard’s Jeff Smith was slated to meet with CEO Bourla, said people familiar with the matter. For executives to join, and then walk away from an activist’s campaign is highly unusual.

It was also not immediately clear what impact, if any, the breakaway would have on Starboard’s campaign. A representative for the activist fund did not immediately return a request for comment. Starboard, one of the largest and most tenacious activist funds, has amassed a roughly $1 billion position in the pharmaceutical firm, CNBC previously reported.

Jeff Smith, the managing member at Starboard, has previously mounted campaigns at Autodesk and Salesforce in recent months. While it typically focuses on the technology sector, it also built stakes in Starbucks and Wall Street Journal parent News Corp this year.

Representatives for Pfizer did not immediately return requests for comment.

This is a developing story. Please check back for updates.



Source

Novo Nordisk’s Ozempic and Wegovy now available in the U.S. after shortages, FDA says
Health

Novo Nordisk’s Ozempic and Wegovy now available in the U.S. after shortages, FDA says

Packages containing syringes of the medications Wegovy, Ozempic and Mounjaro at a shop in Mitte, Germany, July 11, 2024. Picture Alliance | Picture Alliance | Getty Images All doses of Novo Nordisk‘s highly popular weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the U.S. […]

Read More
Fired Disney employee allegedly hacked menu system to falsely claim certain foods did not contain peanuts, complaint says
Health

Fired Disney employee allegedly hacked menu system to falsely claim certain foods did not contain peanuts, complaint says

The “Partners” statue of Walt Disney and Mickey Mouse, at Cinderella Castle at the Magic Kingdom, at Walt Disney World, in Lake Buena Vista, Florida, photographed Saturday, June 3, 2023. Joe Burbank | Tribune News Service | Getty Images A disgruntled former Disney employee is being accused of hacking into menu-creating software used by the […]

Read More
Eli Lilly’s Zepbound and Mounjaro are no longer in shortage. Here’s where their sales still fell short
Health

Eli Lilly’s Zepbound and Mounjaro are no longer in shortage. Here’s where their sales still fell short

Eli Lilly’s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as supply of both medicines have largely recovered from widespread shortages in the U.S.  The reason, according to the company, is not an issue of demand or supply.  Eli Lilly instead blamed disappointing sales on drug […]

Read More